Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quinapril is an angiotensin-converting enzyme (ACE) inhibitor prodrug used primarily to treat hypertension and heart failure. It is also indicated for slowing the progression of renal disease. Quinapril works by inhibiting ACE, which catalyzes the conversion of angiotensin I to angiotensin II—a potent vasoconstrictor—thereby reducing blood pressure and decreasing aldosterone secretion. This leads to vasodilation, reduced sodium and fluid retention, and improved cardiac efficiency. Quinapril was developed as a first-line therapy for high blood pressure and can be used alone or in combination with other antihypertensive agents such as thiazide diuretics or beta blockers[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quinapril.